GlassScriptPhysician profile
Juebin Huang
NPI 1477851996
$20,221.88
in general payments reported to CMS, 2019-2025
39 companies · $1,690 in 2025
The $1,690 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,702 · 2020: $5,056 · 2021: $2,706 · 2022: $3,438 · 2023: $1,922 · 2024: $1,708 · 2025: $1,690.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $4,500 · Food and Beverage: $721 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $4,500.00 |
| Food and Beverage | $721.39 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $11,480.00 | 2019-2025 | |
| Acadia Pharmaceuticals INC | $2,539.14 | 2019-2023 | Nuplazid |
| Amneal Pharmaceuticals LLC | $2,277.96 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $823.55 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Neurocrine Biosciences, INC. | $267.22 | 2020-2024 | Ingrezza, Ongentys |
| Kyowa Kirin, INC. | $260.22 | 2020-2023 | Nourianz |
| Sunovion Pharmaceuticals INC. | $209.33 | 2019-2021 | |
| Supernus Pharmaceuticals, INC. | $202.85 | 2019-2020 | |
| Eisai INC. | $186.30 | 2021-2022 | |
| Amgen INC. | $186.15 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $167.76 | 2022 | |
| Avanir Pharmaceuticals, INC. | $162.93 | 2019-2022 | |
| Ucb, INC. | $159.73 | 2019-2023 | Briviact |
| Mdd US Operations, LLC | $132.88 | 2022-2023 | Xadago, Apokyn |
| Genzyme Corporation | $127.96 | 2021-2023 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Argenx US, INC. | $124.68 | 2022-2024 | Vyvgart |
| Astrazeneca Pharmaceuticals LP | $120.00 | 2022 | |
| Emd Serono, INC. | $106.27 | 2021-2022 | |
| Lundbeck LLC | $103.99 | 2020-2023 | Vyepti |
| Ge Healthcare | $77.94 | 2019-2022 | |
| Greenwich Biosciences, INC. | $66.75 | 2019 | |
| Novartis Pharmaceuticals Corporation | $62.66 | 2019-2023 | |
| Acorda Therapeutics, INC | $49.24 | 2020-2023 | Inbrija |
| Alexion Pharmaceuticals, INC. | $41.95 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $37.44 | 2021 | |
| Upsher-Smith Laboratories LLC | $36.53 | 2020-2021 | |
| Biogen, INC. | $29.85 | 2019-2020 | |
| Abbvie INC. | $29.77 | 2023 | |
| Otsuka America Pharmaceutical, INC. | $24.05 | 2023 | Nuedexta |
| Tg Therapeutics, INC. | $20.78 | 2023 | |
| Boston Scientific Corporation | $20.19 | 2022 | |
| Irhythm Technologies, INC. | $15.96 | 2019 | |
| Sk Life Science, INC. | $15.77 | 2021 | |
| Sumitomo Pharma America, INC. | $15.31 | 2023 | Aptiom |
| Jazz Pharmaceuticals INC. | $14.25 | 2019 | |
| Janssen Pharmaceuticals, INC | $12.81 | 2023 | Ponvory |
| Assertio Therapeutics, INC. | $11.71 | 2020 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Juebin Huang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.